Author

J. Armenia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:clinical cohort / trial· 1 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

J. V. Forment· 2 shared M. J. O'Connor· 2 shared A. Galbiati· 1 shared D. Barrell· 1 shared E. Irving· 1 shared E. Leo· 1 shared Functional Genomics Centre· 1 shared G. Illuzzi· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. V. Forment

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition

K. Jamal, A. Galbiati, J. Armenia, G. Illuzzi, J. Hall, S. Bentouati, D. Barrell, M. Ahdesmäki, Functional Genomics Centre, M. J. O'Connor, E. Leo, J. V. Forment

The paper identifies 110 genes linked to PARP inhibitor sensitivity through CRISPR screens and tumor data analysis, highlighting XRCC3 as a potential biomarker for prostate cancer.

bioRxiv · Jul 29, 2022Cancer Biology

A meta-analysis of clinical cases of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance

L. Tobalina, J. Armenia, E. Irving, M. J. O'Connor, J. V. Forment

This study analyzes reversion mutations in BRCA genes from clinical cases to identify DNA end-joining repair mechanisms linked to therapy resistance and suggests targeting these pathways to improve treatment outcomes.

bioRxiv · Jul 22, 2020Cancer Biology